Skip to main content
Premium Trial:

Request an Annual Quote

Shares in Ciphergen Rise 6.6 Percent on Breast Cancer Diagnostics News

NEW YORK, Dec. 9 (GenomeWeb News) - Shares in Ciphergen Biosystems were up 6.6 percent, or $.06, at $.97 in mid-afternoon trading one day after the company announced plans to develop breast cancer diagnostics.


As GenomeWeb News reported this morning, Ciphergen is developing diagnostics based on a "series of discoveries" that have been made using the company's SELDI technology.


Although no timeline was announced, the company expects to collaborate with the University of College London and UCL BioMedica, Ciphergen said.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.